Foresite Capital
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
In the firm's own words, from its website.
39 additional team members, 37 additional co-investors and affiliates, 204 additional investments, funds and LPs, 43 events, 31 verified contacts (28 professional url, 2 firm phone, 1 published business email)
Every relationship, signal and contact on this record, with the source on each.
7 days of DFX Intelligence free, then $199/month unless canceled. A card is taken when the trial starts.
Regulatory footprint (Form ADV): RAUM $3.2B · 9 private funds · filed Oct 20, 2026 source
Filed a Form D on Jun 23, 2023, for a fund listed on its Form ADV (see the fund).
What matters now
- 2 companiesnew in 12 months
2 new companies in the last 12 months. Latest round KymaThera Series B ($80M round) on Oct 6, 2026.
A firm writing cheques this quarter is one a founder can pitch now.
- 1 companyportfolio raising
One portfolio company has new financing on record in 6 months without this firm named on the round; the latest on Sep 2, 2026.
A portfolio company raising again is a follow-on decision for the firm and a co-investment opening for others.
- 6 dealswith Arch Venture Partners
Invests most often alongside Arch Venture Partners (6 shared deals) and OrbiMed (5 shared deals). 16 of the 40 most frequent co-investors were first seen with it on record in the last 12 months.
pair last observed on record Oct 30, 2026, not a deal date · The firms it syndicates with are the likeliest to see the same deals and to fill out its rounds.
Measuredshared rounds and portfolio companies on recordFor Founders building a round, co-investorsCo-investors → - 18 of 20enter at Series B+
Enters mostly at Series B or later: 18 of 20 first entries on record; its site states multi stage stage.
rounds to Oct 6, 2026 · Tells a founder whether their round is one this firm writes.
People to know
View all people- Managing DirectorWhy: Managing directorProfile
- Managing DirectorWhy: Managing directorProfile
- PartnerWhy: Partner: part of the investment decisionNo route on file yet
Relationship network
360 connected entities25 observed rounds15 repeat counterparties10 dated rounds shown here, 2015 to 2026
From financing rounds and every investor named in them, Form ADV and Form D filings, the firm's funds and team, and disclosed LP commitments in the venture capital graph. A round's amount is the size of the round, not money that moved between two investors.
1 mention in the sources could not be matched to a firm or person, so it is held back from the picture and its summary.
Some relationships on this record are counted rather than named here. They open with the full profile.
Click any name or line for the rounds and sources behind it. Line weight is rounds together; dashed lines are inferred.
- Sponsor
- Company
- Fund or vehicle
- Person
›How strength and recency are read
Co-investors are read from the rounds: three or more shared rounds is a strong observed relationship, two a repeat co-investor, one a single round. Funds and people are structural. Nothing is scored that a reader cannot check.
Darker lines were active in the last 24 months or are current; lighter lines are older or undated.
How am I connected? Published routes
Name your firm, a company or a person, and DFX finds the published routes to Foresite Capital: a shared portfolio company or board, a prior employer, a co-investor, a shared LP or service provider. Every step is a filed or published record with its source; none is a guess about who knows whom.
Public record only. For routes through people you know, see Who can introduce you.
See how you connect to Foresite Capital
7 days of DFX Intelligence free, then $199/month unless canceled. A card is taken when the trial starts.
Investing
177 companies on record, 2 new in 12 months
Investments on record
What these amounts mean“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.Acquired, Public, Exited and Active are what the firm’s own portfolio card says, read on the date shown when you hover the chip; they are not deal dates. A company with no chip is one whose card states no outcome: DFX does not assume it is active.| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| KymaThera | Series B · Series B | participant | unknown | $80.0M | unknown | Oct 6, 2026 | Fact Press release |
| Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics | Series B · Series B | lead | Cindy Xiong (confirmed) | $89.0M | unknown | Mar 26, 2026 | Fact Press release |
| Latigo Biotherapeutics, Inc. | Series B · Series B | participant | unknown | $150M | unknown | Mar 17, 2025 | Fact Press release |
Stated thesis versus observed behaviour
- Sectors
- ai, healthcare, biotech
- Stages
- multi stage
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
People
43 current, 0 departed
Investment team
How the team is orderedPartners who lead rounds first (rounds led, then deals attributed, then seniority), then the rest of the investment team, then investor relations, finance and operations. A person named by two sources under two spellings is shown once.- Dorothy Margolskee · Managing DirectorWhy this person: Managing director; Named with investment responsibility; Confirmed current on the firm's own site 2026-10-12LinkedIn or profile link on file (firm website), confirmed 2026-10-12, confidence 90%
- Michael Rome · Managing DirectorWhy this person: Managing director; Named with investment responsibility; Confirmed current on the firm's own site 2026-10-12LinkedIn or profile link on file (firm website), confirmed 2026-10-12, confidence 90%
- Cindy Xiong · PartnerWhy this person: Partner: part of the investment decision; Named with investment responsibility; Led 1 round on record
Ranked by the role the firm or its filing states, a route on file and deals led. Every reason is read from the record, never inferred. 2 with a route on file. Routes are published by the person or the firm (their bio, the team page or a filing) and are revealed on a plan; data bought from a provider is never shown, and a route printed at a firm the person has since left is held back.
Contacts
1 published business email, 2 firm phone, 28 professional url on record, each with its source. Values open with the complete profile.
Funds and LPs
11 vehicles, 0 LPs disclosed
Funds and vehicles
What these amounts meanGAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Foresite Capital Fund VI LP | Fund | 2022 form d first sale | Active deployment | $1.1B Oct 20, 2026 | 494 | $551M | Jun 23, 2023 |
| Foresite Capital Vi-A, LLC | Feeder or parallel | 2022 adv first reported | Active deployment | $18.0M Oct 20, 2026 | 18 | $0 of $17.2M | Dec 20, 2021 |
| Foresite Labs Fund I, L.P. | Fund | 2021 adv first reported | Mature | $131M Oct 20, 2026 | 97 | $0 of $150M | May 20, 2021 |
Limited partners
Known LPs and allocators
What these amounts and dates areEach commitment is counted once across the pension tape and the allocator graph. A commitment date prints only when the source printed one; otherwise the row carries the report date. A foundation’s 990-PF line is a holding at fair value, never a commitment. Rows without a fund on the venture graph are commitments to this manager.| Allocator | Type | Fund | Amount | Date | Source |
|---|---|---|---|---|---|
| Carnegie Corporation of New York | FOUNDATION | Foresite Capital Fund VI LP | $14.7M fair value on the foundation's return | reported as of Sep 30, 2025 | Fact IRS Form 990 / 990-PF e-file returns |
| Carnegie Corporation of New York | FOUNDATION | Foresite Labs Fund I, L.P. | $2.8M fair value on the foundation's return | reported as of Sep 30, 2025 | Fact IRS Form 990 / 990-PF e-file returns |
| Rita Allen Foundation | FOUNDATION | Foresite Capital Opportunity Fund V, L.P. | $116,948 fair value on the foundation's return | reported as of Dec 31, 2024 | Fact IRS Form 990 / 990-PF e-file returns |
Relationships across DFX
161 co-investors · on 4 other DFX graphs
Co-investors
- 2026-10-306 shared deals · strong
- 2026-10-195 shared deals · strong · they led 1
- 2026-10-194 shared deals · strong · they led 1 · this firm led 1
Compare portfolios with Arch Venture Partners, OrbiMed, RA Capital Management, LP or any firm. Co-investors across the market
Across DFX and the capital chainon 4 other DFX graphs · 61 capital paths ShowHide
- The same institution is held on Allocators, Private Equity, RIA and Wealth, Private Credit, matched by identifier. See which records
Foresite Capital is the same institution as 4 records in Allocators, Private Equity, RIA and Wealth and Private Credit.
DFX found 4 relationships across 4 datasets
Which record it is in each graph, what it is called there, and how the two were matched.
7 days of DFX Intelligence free, then $199/month unless canceled. A card is taken when the trial starts.
Checking your plan…
Foresite Capital sits on 61 traced paths of capital across the graphs.
DFX traced 61 paths of capital through this record
Every record on each path, what it committed or lent, and as of when.
7 days of DFX Intelligence free, then $199/month unless canceled. A card is taken when the trial starts.
Derived from allocator disclosures, BDC schedules and SEC filings; confidence is the weakest hop.
Checking your plan…
Evidence and history
48 dated events, 144 observations from 4 sources
Timeline
- Jul 30, 2026Foresite Public & Crossover Opportunities Fund I, L.P. first reported on Form ADV by Foresite Capital (Venture Capital Fund)Fund first reported on Form ADVFundsInferenceForesite Public & Crossover Opportunities Fund I, L.P.Form ADV
- Sep 28, 2022Foresite Capital Fund VI LP first reported on Form ADV by Foresite Capital (Venture Capital Fund)
- Feb 16, 2022Foresite Capital Vi-A, LLC first reported on Form ADV by Foresite Capital (Venture Capital Fund)
- Aug 23, 2021Foresite Labs Fund I, L.P. first reported on Form ADV by Foresite Capital (Venture Capital Fund)
- Mar 15, 2021Foresite Capital V-A, LLC no longer reported on Form ADV by Foresite Capital
Identity and regulatory footprint
Address, phone, Form ADV filing and ownersForm ADV filed Oct 20, 2026 · 9 private fundsShowHide
- Headquarters
- West Hollywood, CAadviserinfo.sec.gov
- Office address
- unknownadviserinfo.sec.gov
- Business phone
- unknownadviserinfo.sec.gov
- Website
- FORESITECAPITAL.COM
- SEC adviser type
- Registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Oct 20, 2026
- Private funds reported
- 9 (9 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets, adviser total
- $3.2Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $3.2Bthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 40
Classification history
Classification history
Every classification this record has carried2 on recordShowHide
- Sep 23, 2026Multi-stage venture firm (probable, 80%)Both early and growth/opportunity families, reported GAV $3.3B
- Sep 12, 2026Multi-stage venture firm (probable, 80%)Both early and growth/opportunity families, reported GAV $3.5B
Evidence
Every observation behind this profile, with its source, date and class
| Fact | Value | Effective | Class | Source |
|---|---|---|---|---|
| Why admitted | VC funds reported | Jul 30, 2026 | Fact | Form ADV |
| SEC adviser type | Registered investment adviser | Oct 20, 2026 | Fact | Form ADV |
| SEC adviser type | Registered investment adviser | Jul 30, 2026 | Fact | Form ADV |
| SEC adviser type | Registered investment adviser | Jul 30, 2026 | Fact | Form ADV |
| SEC adviser type | Registered investment adviser | Mar 18, 2024 | Fact | Form ADV |
| First Form ADV filing | 2012-03-28 | Oct 20, 2026 | Fact | Form ADV |
| First Form ADV filing | 2012-03-28 | Jul 30, 2026 | Fact | Form ADV |
| First Form ADV filing | 2012-03-28 | Mar 18, 2024 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-11-03 | Nov 4, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-11-02 | Nov 3, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-30 | Nov 1, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-29 | Oct 30, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-28 | Oct 29, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-27 | Oct 28, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-25 | Oct 26, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-23 | Oct 25, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-22 | Oct 24, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-21 | Oct 22, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-20 | Oct 21, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-19 | Oct 20, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-16 | Oct 19, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-12 | Oct 14, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-13 | Oct 14, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-10 | Oct 12, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-09 | Oct 11, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-08 | Oct 10, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-07 | Oct 9, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-06 | Oct 8, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-05 | Oct 6, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-10-02 | Oct 4, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-30 | Oct 1, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-29 | Sep 30, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-25 | Sep 26, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-23 | Sep 24, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-21 | Sep 23, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-22 | Sep 23, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1 | Sep 12, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2026-10-20 | Oct 20, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2026-07-30 | Jul 30, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2026-07-30 | Jul 30, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2024-03-18 | Mar 18, 2024 | Fact | Form ADV |
| SEC status | Approved | Jul 30, 2026 | Fact | Form ADV |
| SEC status effective | 2014-07-07 | Jul 30, 2026 | Fact | Form ADV |
| Venture share of reported funds | 1 | Oct 20, 2026 | Fact | Form ADV |
| Venture share of reported funds | 1 | Jul 30, 2026 | Fact | Form ADV |
| Venture share of reported funds | 1 | Mar 18, 2024 | Fact | Form ADV |
| Business phone | Jul 30, 2026 | Fact | Form ADV | |
| Business phone | Mar 18, 2024 | Fact | Form ADV | |
| Contact page url | Oct 30, 2026 | Fact | ||
| Contact page url | Oct 15, 2026 | Fact | ||
| Contact page url | Sep 30, 2026 | Fact | ||
| Contact page url | Sep 16, 2026 | Fact | ||
| Description | Oct 30, 2026 | Fact | ||
| Description | Oct 15, 2026 | Fact | ||
| Description | Sep 30, 2026 | Fact | ||
| Description | Sep 16, 2026 | Fact | ||
| Description | Sep 14, 2026 | Fact | ||
| Employees | 40 | Jul 30, 2026 | Fact | Form ADV |
| Employees | 54 | Mar 18, 2024 | Fact | Form ADV |
| Headquarters | West Hollywood, CA | Jul 30, 2026 | Fact | Form ADV |
| Headquarters | Larkspur, CA | Mar 18, 2024 | Fact | Form ADV |
| Office address | Jul 30, 2026 | Fact | Form ADV | |
| Office address | Mar 18, 2024 | Fact | Form ADV | |
| Self-described type | Venture capital “America’s Top Venture Capital Firms 2025” | Oct 30, 2026 | Fact | |
| Self-described type | Venture capital “America’s Top Venture Capital Firms 2025” | Oct 15, 2026 | Fact | |
| Self-described type | Venture capital “America’s Top Venture Capital Firms 2025” | Sep 30, 2026 | Fact | |
| Self-described type | Venture capital “America’s Top Venture Capital Firms 2025” | Sep 16, 2026 | Fact | |
| Self-described type | Venture capital “America’s Top Venture Capital Firms 2025” | Sep 14, 2026 | Fact | |
| Legal form | Limited Liability Company | Jul 30, 2026 | Fact | Form ADV |
| Portfolio page | Oct 30, 2026 | Fact | ||
| Portfolio page | Oct 15, 2026 | Fact | ||
| Portfolio page | Sep 30, 2026 | Fact | ||
| Portfolio page | Sep 16, 2026 | Fact | ||
| Portfolio page | Sep 14, 2026 | Fact | ||
| Private funds reported | 9 | Oct 20, 2026 | Fact | Form ADV |
| Private funds reported | 9 | Jul 30, 2026 | Fact | Form ADV |
| Private funds reported | 9 | Jul 30, 2026 | Fact | Form ADV |
| Private funds reported | 9 | Mar 18, 2024 | Fact | Form ADV |
| Private fund gross assets (reported) | $3.2B | Oct 20, 2026 | Fact | Form ADV |
| Private fund gross assets (reported) | $3.2B | Jul 30, 2026 | Fact | Form ADV |
| Private fund gross assets (reported) | $3.2B | Jul 30, 2026 | Fact | Form ADV |
| Private fund gross assets (reported) | $3.5B | Mar 18, 2024 | Fact | Form ADV |
| Regulatory AUM (adviser, not fund size) | $3.2B | Jul 30, 2026 | Fact | Form ADV |
| Regulatory AUM (adviser, not fund size) | $3.5B | Mar 18, 2024 | Fact | Form ADV |
| Schedule a diff | sadiff-1 | Sep 29, 2026 | Fact | Form ADV |
| Stated sectors | AI, healthcare, biotech “sector words on the home page” | Oct 30, 2026 | Fact | |
| Stated sectors | AI, healthcare, biotech “sector words on the home page” | Oct 15, 2026 | Fact | |
| Stated sectors | AI, healthcare, biotech “sector words on the home page” | Sep 30, 2026 | Fact | |
| Stated sectors | AI, healthcare, biotech “sector words on the home page” | Sep 16, 2026 | Fact | |
| Stated sectors | AI, healthcare, biotech “sector words on the home page” | Sep 14, 2026 | Fact | |
| Stated stages | Multi stage “stage words on the home page” | Oct 30, 2026 | Fact | |
| Stated stages | Multi stage “stage words on the home page” | Oct 15, 2026 | Fact | |
| Stated stages | Multi stage “stage words on the home page” | Sep 30, 2026 | Fact | |
| Stated stages | Multi stage “stage words on the home page” | Sep 16, 2026 | Fact | |
| Stated stages | Multi stage “stage words on the home page” | Sep 14, 2026 | Fact | |
| Team page | Oct 30, 2026 | Fact | ||
| Team page | Oct 15, 2026 | Fact | ||
| Team page | Sep 30, 2026 | Fact | ||
| Team page | Sep 16, 2026 | Fact | ||
| Team page | Sep 14, 2026 | Fact | ||
| Venture funds reported | 9 | Oct 20, 2026 | Fact | Form ADV |
| Venture funds reported | 9 | Jul 30, 2026 | Fact | Form ADV |
| Venture funds reported | 9 | Jul 30, 2026 | Fact | Form ADV |
| Venture funds reported | 9 | Mar 18, 2024 | Fact | Form ADV |
| Website | Mar 18, 2024 | Fact | Form ADV | |
| Site title | Oct 30, 2026 | Fact | ||
| Site title | Oct 15, 2026 | Fact | ||
| Site title | Sep 30, 2026 | Fact | ||
| Site title | Sep 16, 2026 | Fact | ||
| Site title | Sep 14, 2026 | Fact |
How this is scored
Scores, classification basis and filing advisersMulti-stage venture firm, probableShowHide
Both early and growth/opportunity families, reported GAV $3.3B
- importance
- gav: 0.76 · funds: 1 · people: 0.8 · investments: 0.85 · co investors: 0.89
- active deployment
- investments 12m: 0.25 · fund raising 18m: 0 · people joined 12m: 0 · vintage within 3y: 0 · latest investment at: 2026-10-06
- emerging manager
- fund count: 25 · reported gav: $3.2B · first adv filing: 2012-03-28 · years since first filing: 14.6
Connected records
Portfolio companies
- KymaThera (since 2026)
- Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics (since 2026)
- Latigo Biotherapeutics, Inc. (since 2025)
174 more on this record
Funds
- Foresite Capital Fund VI LP (vintage 2022)
- Foresite Capital Vi-A, LLC (vintage 2022)
- Foresite Labs Fund I, L.P. (vintage 2021)
22 more on this record
Co-investors
- Arch Venture Partners (6 shared deals)
- OrbiMed (5 shared deals)
- RA Capital Management, LP (4 shared deals)
Fits, record history and connections
scored matches for this investor, every identity change, every edge
Record history
- Adviser's first ADV filing2012-03-28source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.